Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Reasons It's Smart to Buy Celgene's Stock Now

TheMotleyFool

0 0

3 Reasons It's Smart to Buy Celgene's Stock Now

Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider adding Celgene to portfolios, including upcoming data for cancer trials, a promising potential new drug launch in 2018, and a bulletproof balance sheet.

In December, industry leaders will get together to discuss the latest in blood cancer research at the annual American Society of Hematology (ASH) conference.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com